Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 90
Selected: 0
NCT IDTitle
NCT06096116Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT04651400Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
NCT02253082Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)
NCT01125813Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
NCT02875236Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)
NCT04508530Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
NCT03092245Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial
NCT02180763Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
NCT01938378Octaplas Pediatric Plasma Exchange Trial
NCT06429787Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
NCT03656640Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases
NCT01225276Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
NCT02740335Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
NCT00545493Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis
NCT03376516Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
NCT01063595A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD
NCT06361537Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
NCT01888484Study of Octanorm Subcutaneous IG in Patients With PID
NCT01313507High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)
NCT00618098Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
NCT01341912Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)
NCT01863758Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT01712438Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
NCT04411667Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19
NCT03686969Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
NCT01575756Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap
NCT00812565Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
NCT03344003Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
NCT02267226Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
NCT04534751Factor In the Initial Resuscitation of Severe Trauma 2 Patients
NCT04502030Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
NCT04146376Von Willebrand Factor in Pregnancy (VIP) Study
NCT04023019Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04953884Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
NCT03818529ATHN 8: Previously Untreated Patients (PUPs) Matter Study
NCT01859754Octagam 5% Versus Comparator Post Marketing Trial
NCT03793426Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
NCT01992549Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
NCT04918173Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
NCT07220915Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT04640142Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
NCT03988426Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
NCT02962765Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
NCT03369314Observational Study of the Use of octaplasLG®.
NCT00411801Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)
NCT02278575Atenativ Effect on Uterine Blood Flow and Preeclampsia
NCT02972281Systematic Search for Primary Immunodeficiency in Adults With Infections
NCT04376762Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
NCT01012323A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases
NCT03348618A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)